Risk adjusted net present value: What is the current valuation of AstraZeneca’s Rilvegostomig?
Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Bile Duct Cancer (Cholangiocarcinoma).
Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Bile Duct Cancer (Cholangiocarcinoma).
What's Your Reaction?
